Posters
(results will display both Free Papers & Poster)
Efficacy of intracorneal ring segments for the management of keratoconus, post-LASIK ectasia and pellucid marginal degeneration
Poster Details
First Author: L.Daas GERMANY
Co Author(s): M. El-Husseiny A. Langenbucher B. Seitz
Abstract Details
Purpose:
To evaluate the safety and efficacy of intracorneal ring segments (Intacs SK, Addition Technology Inc., Des Moines, IL) in the management of keratoconus, Post-LASIK ectasia and pellucid marginal degeneration (PMD).
Setting:
Department of Ophthalmology, Saarland University Medical Center, Homburg, Germany.
Experimental Ophthalmology, Saarland University, Homburg, Germany.
Methods:
This prospective case series comprised 61 eyes of 52 patients with a mean age of 34.5 ± 11.0 (SD) that had Intacs SK implantation between August 2011 and November 2014. Fifty three patients were keratoconus, 2 patients were PMD and 6 patients had post-LASIK ectasia. All patients had a clear central cornea and suffered from hard contact-lens intolerance. The main outcome measures were uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), refraction and keratometry. The outcomes were evaluated at 6 (N=38), 12 (N=23) and at 24 (N=12) months.
Results:
The mean UCVA improved from 20/200 preoperatively to 20/40, 20/30 and 20/30 after 6, 12 and 24 months, respectively. The mean BSCVA improved from 20/50 to 20/28, 20/25 and 20/25 after 6, 12 and 24 months, respectively. The mean spherical equivalent improved from -9.03 ± 5.58 to -2.37 ± 2.64, -2.42 ± 2.05 and -2.54 ± 1.41 after 6, 12 and 24 months, respectively. The mean Kflat and Ksteep decreased from 47.6 ± 3.6 diopters (D) and 50.7 ± 4.2 D respectively, to 43.5 ± 3.3 D and 47.4 ± 4.5 D after 6 months follow-up and remained stable thereafter.
Conclusions:
Intacs SK implantation appears to be effective in improving the UCVA and BSCVA and at the same time seems to stabilise the ectatic corneal condition in patients with keratoconus, PMD and post-LASIK ectasia.
Financial Disclosure:
NONE